POS0319 PERFORMANCE OF PATIENT REPORTED OUTCOMES (PROs) IN SCLERODERMA PATIENTS WITH REDUCED LUNG FUNCTION IN AN OBSERVATIONAL COHORT

MO Lazzaroni1, G. Abignano2,3, M. Wilson,4 V. Kakkar,5 F. Del Gaido5. ASST Spedali Civili di Brescia, University of Brescia, Rheumatology and Clinical Immunology, Brescia, Italy; 2University of Leeds, Institute of Rheumatic and Musculoskeletal Medicine and NIHR Biomedical Research Centre, Leeds, United Kingdom; 3Azienda Ospedaliera San Carlo, Rheumatology, Potenza, Italy

Background: Patient Reported Outcomes (PROs) are used to capture disease impact on patients, Health Related Quality of Life (HRQoL) and they have been increasingly used as endpoints in clinical trials for Systemic Sclerosis (SSc). The DeSScipher project within the EUSTAR group highlighted dyspnea as one of the determinent to define the overall relevance of an intervention, the performance of the PROs used as secondary endpoints (St. George’s Respiratory Questionnaire [SGRQ]).

Methods: Among distinct commonly used PROs, the performance of the SGRQ showed the efficacy of Nintedanib in reducing the annual rate of FVC loss, as compared to placebo, without significant changes in other secondary endpoints. The SENSICIS trial in SSc-ILD (2) showed the efficacy of Nintedanib in reducing the impact on patients’ Health Related Quality of Life (HRQoL) and they have been included in the SSc programme for SSc. Data included records of periodical visits with scores of different PROs over time and used them to study the correlation with pulmonary function tests (PFTs) and measures of QoL or HRQoL. The percentage of patients with %pFVC >70%, suggesting that mild reductions in FVC might be well tolerated, was compared with the correlation of SHAQ with CHFS, than with Borg score, suggesting a higher weight given to dyspnea.

Results: Complete data were available from 182 visits of 87 SSc patients (41 %pFVC >70%, 36 %pFVC >50% and 46 with limited cutaneous involvement). Mean %pFVC was 95.16 ±24.93 (median 95) and mean %pDLCO was 59.31±16.51 (median 59). Overall, FVC and DLCO showed a moderate correlation with SHAQ (r =-0.36, p<0.001 and r=-0.42, p<0.001 respectively), while Borg score showed a stronger negative correlation with FVC and DLCO (r=-0.42 and r=-0.38, p<0.001 for both). In a sub-analysis of patients grouped by FVC, patients with FVC 50-70% showed a significant correlation of FVC with SHAQ (r=-0.47, p=0.012), which was not present in patients with FVC 70-90% (r=-0.23, p=0.13).VAS-5 dyspnea and Borg were not associated with FVC in these two subgroups of patients.

Inter PROs analysis showed that CHFS score had a stronger correlation with SHAQ than Borg dyspnea score in the overall population (r=0.86 vs. r=0.57, both p<0.001).

Conclusion: The analysis of a single centre prospective cohort of SSC patients, suggests a small inference of lung function in the overall SHAQ. The stronger correlation of SHAQ with CHFS, than with Borg score, suggests a higher weight of hand function on SHAQ in this population with relatively conserved lung function. In patients with %pFVC >70%, the correlation with SHAQ was stronger than in patients with %pFVC >70%, suggesting that mild reductions in FVC might not be perceived by the patients, or at least they might not modify HRQoL as measured by SHAQ.

REFERENCES:


POS0320 USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT


Objectives: The prognosis of anti-melanoma differentiation-associated gene 5 positive dermatomyositis (anti-MDA5+ DM) – associated interstitial lung disease (ILD) is poor and heterogeneity.

Methods: We analyzed data from 246 anti-MDA5+ DM patients from Myositis Study Group-Jiangsu, a multicenter cohort across eighteen tertiary hospitals in Jiangsu province, from March 2019 to October 2020. The primary end point was all-cause death, and the secondary end point was occurrence of rapidly progressive-ILD (rp-ILD). A decision-tree prediction model was developed by using data from 10 hospital of southern region (n=163), with validation by using contemporaneous data from northern region (n=83).

Results: To assess the risk of rp-ILD, we developed a combined risk score, the CROSS score, that included the following values and scores: C-reactive protein (≤8mg/L, 0; >8mg/L, 3), anti-Ro52 antibody (negative, 0; positive, 4), Sex (Female, 0; Male, 2) and Short course of disease (More than 3 months, 0; Less than 3 months, 2). The mortality risk was identified by the CAR score, including Protein (≤8mg/L, 0; >8mg/L, 3), anti-Ro52 antibody (negative, 0; positive, 4), Sex (Female, 0; Male, 2) and Short course of disease (More than 3 months, 0; Less than 3 months, 2). The mortality risk was identified by the CAR score, including Protein (≤8mg/L, 0; >8mg/L, 3), anti-Ro52 antibody (negative, 0; positive, 4), Sex (Female, 0; Male, 2) and Short course of disease (More than 3 months, 0; Less than 3 months, 2).

Conclusion: The CROSS-CAR decision tree model is easy to evaluate the poor prognostic risk in MDAs+ DM patients during any follow-up period. Unnecessary lung examination, such as chest CT scan and arterial blood gas analysis was avoided in low- and medium-risk patients in both discovery and validation cohorts (p < 0.001).

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3514
Division of Rheumatology, Naples, Italy; 10University Hospital Zurich, University of Zurich, Department of Rheumatology, Zurich, Switzerland; 11University of Padova, Rheumatology Unit, Department of Medicine (DIMED), Padova, Italy; 12VA National Medical Research Institute of Rheumatology, Laboratory of Microcirculation and Inflammation, Moscow, Russian Federation; 13University of Pecs, Department of Rheumatology and Immunology, Pecs, Hungary; 14University College London, Royal Free Hospital, Department of Rheumatology, London, United Kingdom; 15Hospital Cochin Paris, Division of Rheumatology, Paris, France; 16"La Sapienza" University, 11Department of Internal Medicine and Clinical Specialties, Rheumatology Unit, Rome, Italy; 17University of Cagliari-Policlinico Universitario, II Chair of Rheumatology, Monserrato, Italy; 18Hamburg Centre for Pediatric Rheumatology, Centre for Paediatric and Adolescent Rheumatology, Hamburg, Germany; 19Oslo University Hospital, Department of Rheumatology, Oslo, Norway; 20Università Politecnica delle Marche and Ospedali Riuniti, Department of Medical Science and Surgery, Section of Clinical Medicine, Ancona, Italy

Background: Hydroxychloroquine (HCQ) is a well-tolerated drug that contributes to downregulating the immune response against autoantigens and it has been used in several autoimmune diseases. In systemic sclerosis (SSc) it is used to treat inflammatory arthritis without proof of efficacy.

Objectives: Our aim was to evaluate the use of HCQ and its impact on Health Assessment Questionnaire disability index (HAQ-DI) and the Cochin Hand Function Status (CHFS), in a large SSc cohort compared to a propensity matched group of SSc patients not using HCQ.

Methods: SSc patients included in the European Scleroderma Trials and Research (EUSTAR) data base treated with HCQ for at least 6 months were evaluated. Demographic and clinical data, concomitant drugs, duration of HCQ treatment and reasons for its discontinuation, HAQ-DI and CHFS (at least 6 months; out of these 3% (50/1636) had at least a baseline and follow-up evaluation) were recorded and were the outcome variables of interest. Statistical analysis was performed using propensity score matching for age, gender, disease duration, corticosteroids, immunosuppressives, vasoactive drugs, DMARDs in a 3:1 control:HCQ ratio. Standard descriptive statistics and Student’s t-test and Chi-square test were used to assess the propensity-matched groups.

Results: 1,636 of 17,805 SSc patients (9.2%) were treated with HCQ for at least 6 months; out of these 3% (50/1636) had at least a baseline and follow-up HCQ-DI evaluation, (and 44/1636 (2.7%) had at least a baseline and follow-up CHFS evaluation. Propensity matching assured that pts were matched for demographic variables such as gender (mean on HCQ vs no HCQ: female:92.0 vs 85.3), age (49.8 vs 49.97yrs) disease duration (8.3 vs 9.1 yrs), limited disease (55.3 vs 62.6%) as well as background medications (P>0.1-0.9). We did not find any significant changes in HAQ or CHFS (difference in slope) over 365 days of treatment, comparing the HCQ-treated group to the non-HCQ treated patients (p=0.240 for both (Figure 1).

Conclusion: Results from the EUSTAR registry showed that HCQ was used by 9.2% of SSc patients. HCQ use did not improve the HAQ or CHFS, comparing HCQ users to non-HCQ users.

Figure 1. HAQ trend and CHFS trend over the time.

Disclosure of Interests: Silvia Bellando Randone: None declared, Holly Wilhalme: None declared, Cosimo Bruni: None declared, Elise Siegert: None declared, Paolo Autu: None declared, Rosaria Irace: None declared, Oliver Distler: None declared, Andrea Doria: None declared, Lidia P Ananieva: None declared, László Czirják: None declared, Christopher Denton: None declared, Yannick Allanore: None declared, Valeria Ricciere: None declared, ALESSANDRA VACCA: None declared, Ivan Foeldvary Consultant of: Gilead, Novartis, Pfizer, Hexal, BMS, Sanofi, MEDAC, Anna-Maria Hoffmann-Void Speakers bureau: Actelion, Patients for Ingelheim, Roche, Merck Sharp & Dohme, Lilly and Mediscape, Consultant of: Actelion, Boehringer Ingelheim, Roche, Bayer, ARXX, and Mediscape, Grant/research support from: Boehringer Ingelheim, Armando Gabrielli: None declared, Marco Matucci-Cerinic: None declared, Daniel Furst: None declared


PO0322 CORRELATION BETWEEN QUANTITATIVE COMPUTED TOMOGRAPHY AND DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS

D. Sambataro1,2, M. Orlandi3, M. Colaci4, L. Malatino1, G. Sambataro1,2, A. Ariasi1, University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy; 1Azienda Ospedaliero Universitaria di Catania, Department of Rheumatology, Catania, Italy; 2Azienda Ospedaliero Universitaria di Catania, Department of Internal Medicine, Catania, Italy

Background: High Resolution Computed Tomography (HRCT) is the gold standard to evaluate Interstitial Lung Diseases (ILDs) extent and severity. Quantitative Computed Tomography (QCT) is a promising tool as it provides an operator-independent assessment of ILD extent. Even if there are emerging data on QCT in Systemic Sclerosis (SSc), its correlation with disease activity (DA) has not been yet studied.

Objectives: To evaluate the correlation between QCT score and DA in an Italian cohort of SSc patients.

Methods: A multicentric, observational study was conducted in three Italian rheumatological centers. Adult SSc patients classified according to the ACR/EULAR 2013 criteria [1] were assessed with pulmonary function tests, HRCT and for DA, CT images were analyzed quantitatively with the denotometric radiomic data obtained through a free open software – Mean Lung attenuation (MLA), Standard Deviation (SD), Kurtosis, Skewness and Lung volume. DA assessment was conducted according to EUSTAR index [2]: a score ≥2.5 was considered indicative of high disease activity.

Age below 18 and pregnancy were considered exclusion criteria. We used Student’s T test to evaluate the means of the parameters, Pearson’s r test for correlations, receiver operating characteristics curve to define the cutoff values of the significant details, and linear regression with constellation test to define the role of the details. P value <0.05 was considered statistically significant.

Results: Sixty patients were enrolled (male 8, female 52), with mean age 53.2 years (SD 15.4) and mean disease duration 5.3 years (SD 4.2). QCT indexes distribution was different in high DA vs low DA SSc patients. In particular mean lung attenuation (MLA, -834.7 vs -812.1, p =0.03), standard deviation (95.9 vs 102, p =0.03), skewness (2.2 vs 1.7, P =0.006) and kurtosis (5.5 vs 3.3, p <0.009) of the parenchymal lung and skewness (3.1 vs 2.8, p =0.03) of the whole lung were statistically different. DA correlates with MLA (r =-0.28, p <0.003), standard deviation (r =-0.21, p <0.02), skewness (r =-0.32, p <0.001) and kurtosis (r =-0.29, p <0.001) of the parenchymal lung and MLA (r =0.25, p =0.06) skewness (r =-0.27, p <0.003), kurtosis (r =-0.21, P <0.02) of the whole lung. The skewness of the parenchymal lung was the QCT index with the best performance in identifying high DA SSc patients (cutoff value ≥1.85; area under the curve 0.74, p =0.005; sensitivity 79.5%, specificity 68.7% accuracy 76.6%)

Conclusion: To our knowledge, this is the first study which correlate the QCT score with DA in SSc patients. Our results suggest that QCT can identify SSc patients with high DA score. Future studies should assess whether QCT can be used for an operator-independent contribution in DA scores with a potential role in clinical practice. Further studies are needed to confirm the data and to better identify the most suitable parameters for the purpose.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.4261

PO0323 ANTI PM-SCL ASSOCIATED AUTO IMMUNE DISEASES: MULTICENTRIC COHORT OF 128 PATIENTS

P. Breillat1, K. Mariampillai2, P. Martins1, P. Legendre1, B. Dunogué1, J. L. Charuel1, M. Miyara3, H. Vanquaethem4, F. Ackermann5, O. Benveniste6, L. Mouton7, H. Nunes8, Y. Allenbach9, Y. Uzunhan10.

1Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Centre de Référence pour les Maladies Auto-immunes Rares, Université de Paris, Médecine Interne, Paris, France; 2Groupe Hospitalier Pitié-Salpêtrière, Centre de Recherche en Myologie, Unité Mixte de Recherche Scientifique 974, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Institut de Myologie, Plateforme d’essais cliniques adultes I-Motion, Paris, France; 3Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire Immunochimie, Paris, France; 4hôpital d’instruction des armées de Bégin,